首页> 外文期刊>Biochemical and Biophysical Research Communications >PTEN overexpression improves cisplatin-resistance of human ovarian cancer cells through upregulating KRT10 expression
【24h】

PTEN overexpression improves cisplatin-resistance of human ovarian cancer cells through upregulating KRT10 expression

机译:PTEN过表达通过上调KRT10表达来提高人卵巢癌细胞的顺铂耐药性

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Multi-drug resistance (MDR) is a common cause of the failure of chemotherapy in ovarian cancer. PTEN, a tumor suppressor gene, has been demonstrated to be able to reverse cisplatin-resistance in ovarian cancer cell line C13K. However, the downstream molecules of PTEN involved in the resistance-reversing effect have not been completely clarified. Therefore, we screened the downstream molecules of PTEN and studied their interactions in C13K ovarian cancer cells using a 3D culture model. Firstly, we constructed an ovarian cancer cell line stably expressing PTEN, C13K/PTEN. MTT assay showed that overexpression of PTEN enhanced the sensitivity of C13K cells to cisplatin, but not to paclitaxel. Then we examined the differently expressed proteins that interacted with PTEN in C13K/PTEN cells with or without cisplatin treatment by co-immunoprecipitation. KRT10 was identified as a differently expressed protein in cisplatin-treated C13K/PTEN cells. Further study confirmed that cisplatin could induce upregulation of KRT10 mRNA and protein in C13K/PTEN cells and there was a directly interaction between KRT10 and PTEN. Forced expression of KRT10 in C13K cells also enhanced cisplatin-induced proliferation inhibition and apoptosis of C13K cells. In addition, KRT10 siRNA blocked cisplatin-induced proliferation inhibition of C13K/PTEN cells. In conclusion, our data demonstrate that KRT10 is a downstream molecule of PTEN which improves cisplatin-resistance of ovarian cancer and forced KRT10 overexpression may also act as a therapeutic method for overcoming MDR in ovarian cancer.
机译:多重耐药性(MDR)是卵巢癌化疗失败的常见原因。 PTEN是一种抑癌基因,已被证明能够逆转卵巢癌细胞系C13K中的顺铂耐药性。但是,尚未完全弄清参与抗逆作用的PTEN的下游分子。因此,我们筛选了PTEN的下游分子,并使用3D培养模型研究了它们在C13K卵巢癌细胞中的相互作用。首先,我们构建了稳定表达PTEN,C13K / PTEN的卵巢癌细胞系。 MTT分析表明PTEN的过表达增强了C13K细胞对顺铂而不是对紫杉醇的敏感性。然后,我们通过共免疫沉淀法检测了在有或没有顺铂处理的情况下,在C13K / PTEN细胞中与PTEN相互作用的差异表达蛋白。在顺铂处理的C13K / PTEN细胞中,KRT10被鉴定为差异表达的蛋白质。进一步的研究证实,顺铂可以诱导C13K / PTEN细胞中KRT10 mRNA和蛋白的上调,并且KRT10和PTEN之间存在直接的相互作用。 KRT10在C13K细胞中的强制表达也增强了顺铂诱导的C13K细胞的增殖抑制和凋亡。此外,KRT10 siRNA阻断顺铂诱导的C13K / PTEN细胞增殖抑制。总之,我们的数据表明,KRT10是PTEN的下游分子,可改善卵巢癌的顺铂耐药性,而强迫性KRT10的过表达也可能是克服卵巢癌MDR的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号